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To characterize the role of BRCA1 in mammary gland development and tumor suppression, a transgenic mouse 
model of BRCA1 overexpression was developed. Using the mouse mammary tumor virus (MMTV) pro-
moter/enhancer, transgenic mice expressing human BRCA1 or select mutant controls were generated. Trans-
genic animals examined during adolescence were shown to express the human transgene in their mammary 
glands. The mammary glands of 13-week-old virgin homozygous MMTV-BRCA1 mice presented the morphol-
ogy of moderately increased lobulo-alveolar development. The mammary ductal trees of both hemizygous and 
homozygous MMTV-BRCA1t340 were similar to those of control non-transgenic littermates. Interestingly, both 
hemi- and homozygous mice expressing a splice variant of BRCA1 lacking the N-terminal RING finger domain 
(MMTV-BRCA1sv) exhibited marked mammary lobulo-alveolar development, particularly terminal end bud 
proliferation. Morphometric analyses of mammary gland whole mount preparations were used to measure 
epithelial staining indices of ~35% for homozygous MMTV-BRCA1 mice and ~60% for both hemizygous and 
homozygous MMTV-BRCA1sv mice versus ~25% for non-transgenic mice. Homozygous MMTV-BRCA1 mice 
showed delayed development of tumors when challenged with 7,12 dimethylbenzanthracene (DMBA), relative 
to non-transgenic and homozygous BRCA1t340 expressing mice. In contrast, homozygous MMTV-BRCA1sv 
transgenic animals were sensitized to DMBA treatment and exhibited a very rapid onset of mammary tumor 
development and accelerated mortality. MMTV-BRCA1 effects on mortality were restricted to DMBA-induced 
tumors of the mammary gland. These results demonstrate in vivo roles for BRCA1 in both mammary gland de-
velopment and in tumor suppression against mutagen-induced mammary gland neoplasia. 
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1.  Introduction 
Approximately 5 to 10% of all breast and ovarian 
cancers can be attributed to highly penetrant, domi-
nantly inherited mutations in specific genes [1,2]. Mu-
tations in the BRCA1 gene are responsible for 45% of 
familial breast cancer and 80% of families predisposed 
to both breast and ovarian cancer [3,4]. The ~220kD 
BRCA1 nuclear phosphoprotein is characterized by an 
N-terminal RING finger domain (Cys3-His-Cys4), two 
nuclear localization signals in exon 11, and an acidic 
C-terminal region containing BRCA1 C-terminus 
(BRCT) domains [5,6]. 
  BRCA1 has been implicated in a broad range of 
cellular activities including DNA repair and recombi-
nation, transcriptional regulation, chromatin remod-
eling, cellular growth control, and genome stability 
[7-9]. The murine BRCA1 protein consists of 1812 
amino acids and exhibits approximately 60% identity 
and 72% similarity with the human BRCA1 protein. 
Northern analysis indicates that the 7.5kb Brca1 tran-
script is expressed in a 14.5- day whole embryo and 
extra-embryonic tissues, and in adult testis and thy-
mus [10]. Brca1 transcripts were detected in adult liver, 
uterus, kidney, lung, mammary gland, and ovary by 
RNase protection and in situ hybridization [10,11]. In 
situ hybridization studies also showed that Brca1 un-
dergoes a complex pattern of developmentally regu-
lated expression, and is expressed in cells undergoing 
both proliferation and differentiation [11]. In the 
mouse ovary, Brca1 expression is positively correlated 
with cellular proliferation and S-phase nuclear PCNA 
staining [12]. Finally, the developmental pattern of 
Brca1 expression suggests that it is involved in prolif-
eration and differentiation in the mouse mammary 
gland [11,13,14]. 
 Studies indicate that murine Brca1 plays a crucial 
role in the early development of mouse embryos. 
Multiple laboratories have disrupted Brca1 by gene 
targeting [15-19]. Although the phenotype of embryos Int. J. Biol. Sci. 2007, 3 
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homozygous for Brca1 mutations varies, all die be-
tween embryonic days 5.5-13.5 with the onset of le-
thality largely dependent on the region where the 
mutation was introduced. However, despite this 
variation in the age of embryonic lethality, all mutant 
embryos suffer similar abnormalities, including cellu-
lar proliferation defects and developmental retarda-
tion. 
  To better understand the function of BRCA1 in 
n o r m a l  b i o l o g i c a l  p r o c e s s e s ,  w e  u s e d  t h e  m u r i n e  
mammary gland as a model system. Transgenic mice 
were developed to overexpress wild type human 
BRCA1 and BRCA1 mutant proteins, under the control 
of the mouse mammary tumor virus (MMTV) LTR, 
during ductal and alveolar morphogenesis. The 
mammary gland phenotypes of these animals were 
characterized to provide insights into the contributions 
of BRCA1 to mammary development. To examine the 
tumor suppressor function of BRCA1 in this model, 
transgenic animals were treated with the carcinogen 
7,12-dimethylbenzanthracene (DMBA). Orogastric 
instillation of DMBA results in a high incidence of 
mammary tumor formation among treated mice [20]. 
Expression of wild-type BRCA1 delayed mammary 
tumor onset, while overexpression of selected mutant 
BRCA1 constructs had either no effect on mammary 
tumor incidence or survival, or resulted in a rapid on-
set of tumors and shortened survival. Our results 
demonstrated that overexpression of wild type human 
BRCA1 in the murine mammary gland provided pro-
tection against carcinogen-induced tumors. A BRCA1 
construct missing the N-terminus predisposed the 
mammary gland to tumor development. These find-
ings suggest that the tumor suppression and prolifera-
tion functions of BRCA1 may not be mediated by the 
same domains of the protein.  
2.  Materials and methods 
Construction of MMTV-BRCA1 Plasmids 
 All pMMTV-BRCA1 constructs (Fig. 1) were cre-
ated by subcloning the BRCA1 cDNAs into the 
pMMTV-LTR expression vector [21]. The wild type 
human BRCA1 and BRCA1t340 cDNAs each contain 
91bp of the 5’ untranslated region (UTR) upstream of 
the ATG start codon. The mutant BRCA1t340 construct 
contains a stop codon at amino acid 340 (1010delA), 
resulting in protein truncation 116 amino acids into 
exon 11. BRCA1t340 is a known disease-causing mu-
tation in humans. BRCA1sv was isolated from a hu-
man testis cDNA library and contains a cryptic splice 
site in exon 5 [22,23]. This alternative splicing causes 
translation to begin at exon 6 (amino acid 72 of wild 
type BRCA1), resulting in the loss of the N-terminal 
RING finger domain of the protein. The pMMTV vec-
tor has previously been demonstrated to be effective 
for transgene expression in mice [21,24-26]. The entire 
5.7kb BRCA1 cDNA was subcloned into the 5.9kb 
pMMTV LTR promoter/enhancer vector [21] at the Sal 
I restriction site to create the pMMTV-BRCA1 con-
struct. The pMMTV-BRCA1sv construct was created in 
a similar manner. The 1.1 kb BRCA1t340 deletion mu-
tant cDNA was created by polymerase chain reaction 
amplification of the N-terminal 340 amino acids from 
acids from the full-length BRCA1 cDNA using modi-
fied primers (5’ GAA TTG TGT CGA CAT GCG GCC 
G 3’ and 5’ GGC GCC GTC GAC CTA GCT AGC TAC 
CTT TTT TCT GTG CTG GGA GTC C 3’) containing 
Sal I restriction sites. 
 
Figure 1. MMTV-BRCA1 transgenic constructs. Diagram 
of the BRCA1 cDNAs used for the generation of transgenic 
animals. The expression of wild type BRCA1, BRCA1sv (70 
amino acid N-terminal deletion), and BRCA1t340 (BRCA1 
C-terminal truncation mutant) are controlled by the 
MMTV-LTR promoter. The BRCA1 cDNAs were each 
inserted into the third exon of the rabbit ß-globin gene (β-g). 
The bar indicates the RING finger motif, the hatched region 
corresponds to the nuclear localization signals and the nega-
tive symbols (-) indicate the negatively charged C-terminal 
domain with transactivation function. 
Generation and Maintenance of BRCA1 Transgenic 
Mice 
The Xho I BRCA1 fragments were microinjected 
into the male pronucleus of (C57BL/6x DBA/2) F1 
fertilized mouse embryos and implanted into pseu-
dopregnant ICR surrogate mice by the Vanderbilt 
Transgenic/ES Cell Shared Resource Facility. Founder 
m ic e w ere b r ed t o  C 57 BL / 6 mice to establish trans-
genic lines. All animals used in these studies were 
handled in strict compliance with Vanderbilt Univer-
sity Animal Care Committee regulations. 
Identification of Transgenic Founders 
Transgenic animals were identified by Southern 
blot analysis or by PCR. For Southern analysis, 5µg of 
mouse tail genomic DNA (obtained from Meto-
fane-anesthetized 3-week-old mice as described pre-
viously [27] were digested with Alu I and separated on 
an agarose gel. The DNA was transferred to Hy-
bond-N Nylon membranes (Amersham) and hybrid-
ized in QuikHyb Solution (Stratagene) with a 
32P-random primed-labeled 533bp Sal I / Xho I rabbit 
ß-globin probe, excised from the pMMTV vector. 
To identify transgenic animals by PCR, 1µl of 
genomic tail DNA was added to a 50µl reaction vol-
ume [1x PCR buffer II, 1.5mM MgCl2, 200nM each of 
rabbit ß-globin forward 5’ GTC TCG GAT CCT CAG 
AAG GTG GTG GCT GGT GTG G 3’ and rabbit 
ß-globin reverse 5’ GAA CTA GGT ACC GGC ATA 
TGT TGC CAA ACT CTA AAC C 3’ primers, 200µM 
each dNTP, and 2.5 units of AmpliTaq DNA poly-
merase (Perkin-Elmer)]. Cycling conditions consisted 
of 94oC for 6 min, followed by 25 cycles of 94oC for 30 Int. J. Biol. Sci. 2007, 3 
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sec, 64oC for 60 sec, and 72oC for 90 sec, and a final 
extension at 72oC for 3 min. The PCR product was a 
260bp fragment of the rabbit ß-globin exon 3 contained 
in the transgene construct. 
The copy number of founder transgenic animals 
was estimated by determining the amounts of DNA 
equal to one copy of the integrated transgene. The ap-
proximate number of base pairs of the promoter and 
transgene injected (8400bp for MMTV-BRCA1 and 
MMTV-BRCA1sv; 3860bp for MMTV-BRCA1t340) was 
divided by the approximate size of the mouse haploid 
genome (3 x 10 9 bp). Thus, 2.8pg of the pro-
moter/transgene fragment is equal to approximately 
one copy of the integrated MMTV-BRCA1 or 
MMTV-BRCA1sv transgenes per 1µg of genomic DNA, 
while 1.3pg is equal to approximately one copy of the 
integrated MMTV-BRCA1t340 transgene per 1µg of 
genomic DNA. The relative intensity of probe hy-
bridization was compared using a Bio-Rad Model GS 
670 Imaging Densitometer. 
Determination of Stage of Mouse Estrous Cycle 
Vaginal smears were performed using 100µg 
0.9% saline and a plastic transfer pipet. Sloughed cells 
were spread on a glass slide, stained with hematoxylin 
and eosin, and examined by light microscopy to de-
termine stage of the estrous cycle (proestrus, estrus, 
metestrus I, metestrus II, or diestrus) [28]. 
Isolation of Total RNA from Murine Tissues and 
Northern Blot Analysis 
Female transgenic (MMTV-BRCA1, 
MMTV-BRCA1sv, MMTV-BRCA1t340) and nontrans-
genic female mice were anesthetized and sacrificed by 
cervical dislocation to determine mammary gland 
phenotype. Mammary glands, salivary glands, lung, 
and kidneys were removed and used for RNA isola-
tion, in TRI REAGENT [29,30] and analysis of trans-
gene expression was performed by Northern blot. 
Twenty µg of total RNA was separated on a 1% aga-
rose-formaldehyde gel. Following electrophoresis the 
gel was transferred to Hybond-N Nylon membranes 
and hybridized to 32P-random primed-labeled probes 
for human BRCA1 (2.3kb Kpn I / Sac I BRCA1 frag-
ment [exon 11-15] or 1.1kb Sal I BRCA1t340 fragment 
[exon 2 to first 116 amino acids of exon 11], and rat 
cyclophilin (700bp Bam H I /Hind III 1B15 cDNA [31]) 
with Quik Hyb Solution. Blots were washed twice in 
1X SSC + 0.1% SDS at 65oC for 15 min each, followed 
by five washes in 0.2X SSC + 0.1% SDS at 65 oC for 30 
min each. The blots were exposed to Kodak BioMax 
MR film and analyzed for transgene expression. 
Mammary Gland Whole Mount Preparations 
For morphologic analysis, dissected mouse tho-
racic mammary glands were placed into tissue cas-
settes and fixed overnight in freshly prepared 4% 
para-formaldehyde. The glands were defatted in ace-
tone, hydrated in ethanol, and stained in a modified 
Weiger’s iron hematoxylin stain. Tissues were de-
stained and stored in methyl salicylate until photo-
graphed on an Olympus SXH10 Research Stereo Mi-
croscope using Kodak Ektachrome 64T EPY 135-36 
slide film [26]. 
Histology 
M o u s e  t h o r a c i c  m a m m a r y  g l a n d s  w e r e  e x c i s e d  
and fixed overnight in 4% para-formaldehyde. The 
glands were dehydrated in a series of alcohols, em-
bedded in paraffin, sectioned, and stained with he-
matoxylin and eosin. Digital images of the stained 
mammary gland sections were captured with a Leaf 
Lumina brightfield digital camera attached to a Zeiss 
Axiophot Upright Microscope. 
Quantification of Observed Morphology in Mammary 
Glands 
Images of mammary gland whole mount prepa-
rations were imported into a Macintosh computer us-
ing a Polaroid SprintScan 35 slide scanner and the 
epithelial content was quantitated. The amount of 
ducts and terminal end buds present was scored using 
Photoshop-based image analysis, which allows the 
identification of chromogens on the basis of their RGB 
spectral characteristics as well as their saturation, hue, 
and luminosity. Quantification of the chromogen in at 
least three digital representative fields (10X magnifi-
cation) was performed. The tolerance level of the 
Magic Wand tool was adjusted so that all the ducts 
were selected. Spatial information can be inferred for 
the iron hematoxylin since t h e  n u m b e r  o f  p i x e l s  r e -
flects a surface area on the image. The percentage of 
staining in the mammary gland whole mount prepa-
rations (staining index) was calculated by dividing the 
number of pixels of epithelial staining by the pixels of 
the entire sample. This method has been demonstrated 
to be accurately applicable for quantification and 
complete separation of individual chromogens.  
DMBA Treatments  
Mice were given DMBA in 100 μl of corn oil by 
orogastric lavage. The dose regime was 1 mg 
DMBA/mouse per week for 6 weeks beginning at 8 
weeks of age [20]. Mice were examined weekly for 
palpable tumors and morbidity. Mice were sacrificed 
when tumors reached ~1 cm in diameter. Moribund 
mice were sacrificed and necropsies were carried out 
immediately. In nearly all cases these mice were dis-
covered to have lymphoma at necropsy, and many had 
microscopic mammary tumors that were not palpable. 
All visible tumors and other tissues were fixed for 
routine histopathological examination. 
Statistical Analysis 
The average of the percent-stained ductal struc-
tures and buds in mammary gland whole mounts for 
each animal was entered into the SAS statistical pack-
age. The data was normalized by log transformation 
and analyzed with the GLM (general linear models) 
procedure using the method of least squares. In par-
ticular, the ANOVA (analysis of variance) method for 
unbalanced data was used to obtain p values. The time 
to first palpable tumor in the different groups was 
compared using a Kaplan-Meier test. P< 0.05 was con-Int. J. Biol. Sci. 2007, 3 
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sidered statistically significant. For mammary tumor 
specific endpoints we considered all mice that had 
developed a mammary tumor whether or not it was 
the cause of death. 
 
Figure 2. MMTV-BRCA1 transgenic mouse lines. 
Southern hybridization of 10µg of genomic DNA from 
MMTV-BRCA1 (lines 5 and 6), MMTV-BRCA1sv (lines 61 
and 90), and MMTV-BRCA1t340 (lines 1 and 2) animals 
was performed to estimate transgene copy number. The 
approximate copy number of each is indicated below the 
lane. 
3.  Results 
Generation of MMTV-BRCA1 Transgenic Mice 
  Transgenic mice expressing wild type human 
BRCA1 and mutants (BRCA1t340 and BRCA1sv) un-
der the control of the MMTV LTR promoter/enhancer 
were created by microinjecting the linear DNA con-
structs (Fig. 1) into the male pronuclei of single cell 
(C57BL/6 x DBA/2) F1 embryos. 
  Potential founder pups were screened by either 
PCR or Southern blot analysis using DNA extracted 
from tail biopsies. Founder mice were bred to C57BL/6 
mice to produce F1 progeny. Two lines per construct 
were established to control for insertional variation. 
Transgene copy number was estimated by densi-
tometric scanning of Southern blots hybridized with a 
32P-labeled rabbit ß-globin probe (Fig. 2). The 
MMTV-BRCA1 line 5 has approximately 5 copies of 
the transgene integrated, while line 6 has 15 copies. 
The MMTV-BRCA1t340 line 1 has approximately 1 
copy of the transgene and line 2 has approximately 10 
copies. The copy number of the transgene for the 
MMTV-BRCA1sv mice was also estimated to be 20 
copies for line 61 and 15 copies for line 90. 
Expression of the Transgene 
  Hemizygous and homozygous MMTV-BRCA1, 
MMTV-BRCA1t340, and MMTV-BRCA1sv mice ap-
peared healthy and exhibited normal behavior. The 
mice were fertile and the females were able to lactate 
and nurse their young. To date, neither hemizygous 
nor homozygous transgenic mice have developed tu-
mors. 
 Northern hybridization analyses were performed 
to demonstrate expression of the transgene mRNA, 
which may be expected to vary with the number of 
copies integrated and the location of integration. To 
control for varying levels of expression, animals from 
two transgenic lines were evaluated for each construct. 
The ~ 5.6kb human BRCA1 transgene was expressed in 
the mammary glands of 13-week-old virgin 
MMTV-BRCA1 transgenic animals, but not in wild 
type littermates (Fig. 3A). No cross-reactivity with 
endogenous mouse Brca1 was observed with the 
C-terminal BRCA1 transgenic probe (~70% identity to 
mouse Brca1). Although both MMTV-BRCA1 (line 6) 
and MMTV-BRCA1sv (line 90) were estimated to each 
have 15 copies of transgene integrated into the mouse 
genome, there was significantly higher expression of 
transgene mRNA (Fig. 3C) in MMTV-BRCA1sv (line 
90) animals. 
 
Figure 3. Northern analysis of 
MMTV-BRCA1 transgenic mice. 
(A) The mammary glands of 
13-week-old virgin 
MMTV-BRCA1 (line 6) trans-
genic animals in diestrus were 
analyzed for transgene mRNA 
expression with a radiolabeled 
BRCA1 cDNA probe. The ~5.6kb 
BRCA1 transgene mRNA is pre-
sent in transgenic animals, but not 
in nontransgenic controls. Ho-
mozygous transgenic mice express 
more human BRCA1 mRNA than 
hemizygous mice. Hybridization 
to cyclophilin was performed to 
control for RNA loading on the gel. 
(B) The mammary glands of 
13-week-old hemizygous 
MMTV-BRCA1t340 animals (line 2) were analyzed for transgene mRNA expression by Northern hybridization with a ra-
diolabeled BRCA1t340 cDNA probe during different stages of the estrous cycle. BRCA1t340 expression is observed in 
transgenic mice, but not in nontransgenic controls. (C) The mammary glands of 13-week-old virgin hemizygous 
MMTV-BRCA1 (line 6) and MMTV-BRCA1sv (line 90) animals in diestrus were analyzed for transgene mRNA expression 
with a radiolabeled BRCA1 cDNA probe. Despite similar transgene copy numbers, MMTV-BRCA1sv (line 90) mRNA is at a 
significantly higher level than MMTV-BRCA1 (line 6) mRNA. Int. J. Biol. Sci. 2007, 3 
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Figure 4. Northern analysis of transgene expression in 
mouse tissues. (A) The ~1.1kb BRCA1t340 mRNA is de-
tected in mammary gland, salivary gland, and lung of 
13-week-old virgin homozygous MMTV-BRCA1t340 (lines 
1 and 2) transgenic mice. Transgene expression in kidney 
was not observed. (B) In addition to the mammary gland, the 
~5.6kb BRCA1 or BRCA1sv mRNA is present in the sali-
vary gland and lung of 13-week-old virgin homozygous 
MMTV-BRCA1 (lines 5 and 6) and MMTV-BRCA1sv 
(lines 90 and 61) transgenic animals. Transgene expression 
in kidney was not observed (data not shown). 
 
  Thirteen-week-old virgin MMTV-BRCA1t340 
transgenic mice expressed the ~1.1kb human 
BRCA1t340 mRNA in their mammary glands (Fig. 3B). 
The human N-terminal BRCA1 cDNA probe was spe-
cific for sequences expressed from the transgene and 
did not recognize endogenous ~7kb mouse Brca1 
mRNA. Although this N-terminal probe shows ~80% 
identity to mouse Brca1, the mouse transcript was not 
detected under the high stringency conditions used for 
hybridization.  In an attempt to increase the expres-
sion of human BRCA1 transcripts, hemizygous trans-
genic mice were bred to homozygosity. Homozygous 
mice were identified for MMTV-BRCA1 (lines 5 and 6), 
MMTV-BRCA1t340 (lines 1 and 2), and 
MMTV-BRCA1sv (lines 61 and 90) animals using FISH 
performed on interphase nuclei isolated from white 
blood cells (data not shown) to confirm Southern blot-
ting results. 
  Northern blot analysis of total RNA from mam-
mary glands demonstrated that homozygous 
MMTV-BRCA1 transgenic mice expressed higher lev-
els of transgene RNA than hemizygous mice (Fig. 3A). 
Even though the mice were estrous cycle 
stage-matched some variability in the expression of the 
BRCA1 transgene within and between the various 
transgenic lines was observed. 
 Transgene expression was also detected in mouse 
salivary gland and lung of 13-week-old virgin trans-
genic mice (Fig. 4A and B). Hybridization was not ob-
served in kidney RNA from transgenic nor wild type 
animals using either the 1.1kb N-terminal BRCA1t340 
cDNA probe (Fig. 4A) or the 2.3kb C-terminal BRCA1 
cDNA probe (data not shown). Although the MMTV 
LTR promoter has been shown to direct low level 
transgene expression in the epithelial cells of the kid-
ney, other investigators have also reported the lack of 
detectable transgene mRNA in the kidney in their 
studies with MMTV transgenic mice [26,27]. 
Consequences of MMTV-BRCA1 Transgene Expres-
sion 
 Since the MMTV LTR is steroid responsive, mice 
were examined at the same stage of the estrous cycle. 
The phase of the mouse estrous cycle was determined 
by obtaining vaginal smears [28]. The stages that 
vaginal cells undergo are representative of parallel 
changes in the entire reproductive tract. To determine 
the effect of expression of the different transgenes on 
mammary ductal structure, transgenic and nontrans-
genic female mice were sacrificed at 7, 13, and 24 
weeks of age. The thoracic mammary glands were 
removed for whole mount analysis of ductal mor-
phology. A minimum of three mice were examined in 
all experimental groups. 
  Characterization of whole mount preparations 
from 7- and 24-week old virgin MMTV-BRCA1 and 
MMTV-BRCA1t340 hemizygous transgenic animals 
displayed normal ductal architecture. At 24 weeks the 
ducts were observed to fill the entire mammary fat pad, 
as expected. Ductal elongation and development of the 
branching structure appeared to be the same in these 
hemizygous mice compared to nontransgenic animals. 
At 24 weeks, the ducts reached the periphery of the 
pad and the end buds regressed to form terminal 
ductal structures. 
 By contrast, the mammary glands of 13-week–old 
homozygous MMTV-BRCA1 animals appeared to 
have additional lateral branches and acini compared to 
age-matched hemizygous and nontransgenic mice. 
This difference in morphology was not seen in homo-
zygous 13-week-old MMTV-BRCA1t340 mice, which 
had mammary glands indistinguishable from those of 
hemizygous and nontransgenic animals (Fig. 5A, first 
two columns). Histological analysis (Fig. 5B, first two 
columns) confirmed the results of the mammary gland 
whole mount preparations. Greater numbers of acini 
were present in homozygous MMTV-BRCA1 animals 
than in hemizygous MMTV-BRCA1 mice, nontrans-
genic controls or hemi- or homozygous 
MMTV-BRCA1t340 mice. 
  Interestingly, the extent of lobulo-alveolar de-
velopment in homozygous MMTV-BRCA1 mice was 
significantly less than observed in age- and estrous 
stage- matched MMTV-BRCA1sv mice (Fig. 5A, last 
column). The mammary glands of both virgin he-
mizygous and homozygous MMTV-BRCA1sv mice 
exhibited increased lateral branching and alveolar Int. J. Biol. Sci. 2007, 3 
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structures forming from the terminal regions of the 
ducts. Compared to nontransgenic littermate controls, 
hemizygous and homozygous MMTV-BRCA1sv mice 
exhibited a phenotype of secondary branching and 
lobulo-alveolar development similar to that observed 
in pregnant animals. This phenotype is observed in 
both 7- and 13-week-old virgin mice in the estrus and 
diestrus stages of the estrous cycle. These findings 
were also evident upon histologic staining with he-
matoxylin and eosin (Fig. 5B, last column). The results 
suggest that the epithelium of 13-week-old 
MMTV-BRCA1sv mammary glands resembles mor-
phologically the state of epithelium present in a nor-
mal gland at mid-pregnancy. By 24 weeks of age, 
mammary glands were similar in appearance for all 
animals and involution of the glands with aging ap-
peared normal. This suggests that BRCA1 overexpres-
sion did not cause mammary hyperplasia per se, but 
rather accelerated normal development.   
 
Figure 5. Morphological appearance of mammary glands from MMTV-BRCA1 transgenic mice. (A) Iron hematoxy-
lin-stained whole mount preparations from the thoracic mammary gland of 13-week-old virgin nontransgenic, hemizygous, 
and homozygous MMTV-BRCA1, MMTV-BRCA1t340, and MMTV-BRCA1sv transgenic mice in the diestrus phase of the 
estrous cycle are shown. Homozygous MMTV-BRCA1 mice demonstrate additional branching and end buds compared to 
hemizygous and wild type controls. There is an apparent morphological difference in the mammary ductal tree among ho-
mozygous and hemizygous MMTV-BRCA1t340 mice and wild type controls. The mammary glands of both hemizygous and 
homozygous MMTV-BRCA1sv mice show more marked proliferation, and resemble those of a 12.5-day pregnant animal. 
Magnification of the whole mounts is 10X. (B) Representative sections of 13-week-old virgin mammary glands from non-
transgenic, hemizygous, and homozygous MMTV-BRCA1, MMTV-BRCA1t340, and MMTV-BRCA1sv mice are shown. 
The mammary glands of homozygous MMTV-BRCA1 mice contain more alveoli than hemizygous, nontransgenic, or 
MMTV-BRCA1t340 mice. The mammary glands of both hemizygous and homozygous MMTV-BRCA1sv mice contain 
numerous alveoli. Photographs were taken with a 20X objective. 
 
Quantification of Observed Morphology in Mammary 
Glands 
  To confirm and extend qualitative observations 
of morphologic alterations in transgenic mice, epithe-
lial tissue in mammary gland whole mount prepara-
tions was quantified by Photoshop-based image 
analysis [32,33]. The areas selected for image analysis 
were those in which the staining intensity allowed 
unambiguous differentiation between mammary 
ducts/end buds and stroma. 
 Results from this analysis revealed that the ductal 
structures and buds of 13-week-old homozygous 
MMTV-BRCA1 mice (lines 6 and 5) represented ~35% 
of the mammary gland, versus ~25% for nontransgenic 
and hemizygous mice (Fig.6; p=0.004 for line 6 and 
p=0.01 for line 5). MMTV-BRCA1t340 (lines 1 and 2) 
hemi- and homozygous transgenic mice gave quanti-
tative results similar to those of nontransgenic litter-
mates (Fig. 6; p=0.5 for line 1 and p=0.313 for line 2). 
However, the amount of lobulo-alveolar tissue in 
MMTV-BRCA1sv mice resembled those of normal 
mice during mid-pregnancy. Ductal and lobular tissue 
in hemi- and homozygous MMTV-BRCA1sv mice oc-
cupied ~60% (Fig. 6; p=0.009) of the mammary gland, 
comparable to the result of ~70% obtained for 12.5-day 
pregnant mice (data not shown). 
 Since the MMTV LTR is known to be upregulated 
during pregnancy, we evaluated mammary gland 
morphology by whole mounts at various time points 
during pregnancy. All transgenic mice (five or three at 
pregnancy day 3, 7, 12, 19, and five at 1 day 
post-partum) and non-transgenic mice (two at day 10, Int. J. Biol. Sci. 2007, 3 
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five at day 13, three at day 19 and four at 2 day 
post-partum) were evaluated by this approach. There 
were no significant morphological differences (data 
not shown) in the mammary glands among the trans-
genic animals when compared to nontransgenic con-
trols evaluated during pregnancy or lactation.  
 
Figure 6. Quantification of epithelium in mouse mam-
mary glands. The mammary glands of homozygous 
MMTV-BRCA1 mice exhibit ducts with increased branch-
ing and lobulo-alveolar structures compared to nontrans-
genic and hemizygous controls. Homozygous 
MMTV-BRCA1t340 mice have mammary glands that ap-
pear similar to those of nontransgenic and hemizygous ani-
mals. The mammary glands of homozygous 
MMTV-BRCA1sv mice display a phenotype resembling that 
observed in hemizygous mice. At least 3 animals were ex-
amined for each bar. 
 
Effect of Transgene Expression on DMBA Induced 
Mammary Tumor Incidence. 
Treatment of 56-day-old mice with the chemical 
mutagen DMBA resulted in a high incidence of 
mammary tumor development (Fig. 7A). In addition to 
mammary tumor induction, DMBA treated mice also 
developed a variety of tumors in other tissue types, 
most notably lymphoma (Fig. 7B) as has been reported 
previously [20]. When the mammary tumor survival 
data of all homozygous MMTV-BRCA1 and 
MMTV-BRCA1sv transgenic lines were compared 
against nontransgenic controls, a highly significant 
effect on mortality was noted (Fig. 7A, P<0.0001 for 
both lines versus nontransgenic controls). However, 
while homozygous MMTV-BRCA1 mice (lines 5 and 6) 
showed delayed onset against DMBA-induced mam-
mary tumors, expression of BRCA1sv (lines 90 and 61) 
greatly worsened the outcome of these mice for 
mammary cancer. There was no significant difference 
in mortality due to mammary tumors between 
MMTV-BRCA1t340 (line 1) and nontransgenic mice 
(Fig. 7A). The observed effect on mortality was re-
stricted to mammary tumors. When mortality from all 
cancers was pooled, there was no significant difference 
among any transgenic line relative to nontransgenic 
controls (Fig. 7B, P= 0.0715). Similar results are ob-
tained if the MMTV-BRCA1t340 lines are omitted from 
the statistical analysis and only the wild-type and 
splice variant lines are compared against the non-
transgenic controls (data not shown, mammary tumors 
P< 0.001; all tumor types P= 0.4199). We chose the 
endpoint of death or onset of palpable tumor, to insure 
t h a t  w e  c a p t u r e d  m i c e  t h a t  d i e d  o f  l y m p h o m a  a n d  
were shown to have occult mammary tumors on ne-
cropsy. The spectrum of tumors that developed was 
typical for DMBA carcinogen exposure. The majority 
of mammary tumors were adenosquamous carcinomas 
or adenocarcinomas as shown in Fig. 7C and 7D.  
4.  Discussion 
 Wild-type Brca1 undergoes a complex pattern of 
regulated expression, and is expressed in cells under-
going both proliferation and differentiation such as the 
otic vesicle, neuroectoderm, and keratinocytes [11,13]. 
The up-regulation of Brca1 transcripts during preg-
nancy is associated with ductal and glandular prolif-
eration of the mouse mammary gland [34]. In the adult 
male mouse, Brca1 is expressed in tissues undergoing 
proliferation and/or terminal differentiation such as 
the testis [34,35]. 
  Previously, several independent null alleles of 
mouse Brca1 have been generated. Each homozygous 
mutant was an embryonic lethal [15-19]. Homozygous 
Brca111 mutant embryos display abnormalities, par-
ticularly absence of mesoderm formation and gas-
trulation [17]. Growth of homozygous mutant Brca15-6 
or  Brca111 blastocysts in vitro was also severely im-
paired [16,17]. Results from the deletion of a larger 
portion of Brca1 exon 11 suggest that Brca1 is impor-
tant for the differentiation of neuroepithelial cells 
during neural tube formation [15]. 
 Selective disruption of Brca1 in mouse mammary 
epithelial cells results in increased apoptosis and ab-
errant ductal development during pregnancy, lactation, 
and involution [36]. Transgenic mice expressing an 
MMTV-driven, truncated Brca1 display a delay in lac-
tational mammary gland development [14]. In par-
ticular, the mammary glands are smaller than normal 
and the ducts do not completely fill the fat pad. These 
findings suggest that Brca1 is required for normal 
morphogenesis of the mammary gland during preg-
nancy. It should be noted that we did not observe any 
delayed development in mice expressing a truncated 
human BRCA1 transcript.   
  In this study we generated transgenic mice that 
overexpress BRCA1 or BRCA1 mutants (BRCA1t340 
and BRCA1sv) in the mammary gland under the con-
trol of the MMTV LTR promoter/enhancer. Homozy-
gous, but not hemizygous, MMTV-BRCA1 transgenic 
virgin mice demonstrated moderately increased 
mammary lobulo-alveolar epithelium by 13 weeks of 
age. Both hemizygous and homozygous 
MMTV-BRCA1t340 mice had mammary ductal trees 
that were similar to those of control nontransgenic 
littermates. However, both hemi- and homozygous 
MMTV-BRCA1sv transgenic mice exhibited preco-
cious secondary branching and lobular-alveolar de-
velopment, particularly terminal end bud proliferation 
and lobule formation. Results of the analysis on the Int. J. Biol. Sci. 2007, 3 
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mammary gland whole mount preparations indicated 
that the lobulo-alveolar morphology observed in the 
hemizygous and homozygous MMTV-BRCA1sv mice 
was similar to that achieved by mid-pregnancy in 
nontransgenic mice. Homozygous MMTV-BRCA1 
mice displayed an intermediate phenotype. As the 
mice aged, the differences became less prominent, and 
by 24 weeks of age, mammary glands were similar in 
appearance for all animals and involution of the 
glands with aging appeared normal.   
 
Figure 7. Tumor specific survival and histology for MMTV-BRCA1 transgenic lines. Kaplan-Meier curves plotting 
tumor-free survival versus day for mice subjected to a DMBA treatment, (A) mammary tumors, (B) and all tumor types. L5 & 
L6 = MMTV-BRCA1 mice (n=95), NT = nontransgenic mice (n=205), L90 & L61 = MMTV-BRCA1sv mice (n=97), L1 = 
MMTV-BRCA1t340 mice (n=125). (C) Mammary gland adenosquamous carcinoma that developed in a DMBA-treated 
MMTV-BRCA1t340 female (line 2 F58). (D) Mammary gland adenocarcinoma that developed in a DMBA-treated 
MMTV-BRCA1 female (line 5 F185). Original magnification = 100X 
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  The phenotype observed in MMTV-BRCA1 and 
MMTV-BRCA1sv transgenic mice may be caused by a 
number of factors or a combination of factors. Both 
MMTV-BRCA1 (line 6) and MMTV-BRCA1sv (line 90) 
mice are estimated to contain 15 copies of their respec-
tive transgenes. However, Northern analysis revealed 
that BRCA1 mRNA is expressed at significantly higher 
levels in MMTV-BRCA1sv (line 90) mice than in the 
MMTV-BRCA1 (line 6). This may be due to the activity 
of the integration site, as integration of a transgene into 
a region of heterochromatin, such as near the centro-
mere or into satellite DNA can silence gene expression 
[37]. Alternatively, the difference in mRNA expression 
may be due to differences in the structures of the 
transgene constructs.  The MMTV-BRCA1 construct 
contains 91bp of the human BRCA1 5’ untranslated 
region (UTR) upstream of the ATG start codon, while 
the MMTV-BRCA1sv construct contains 38bp of the 
UTR separated by an 89bp insert just prior to the be-
ginning of wild type BRCA1 exon 2. The 89bp insert is 
part of BRCA1 alternative exons 1a and 1b [38,39]. It is 
possible that the 89bp alternative exon contains motifs 
that affect the expression of BRCA1sv. Alternatively, 
the wild type BRCA1 5’ UTR may contain motifs that 
allow for negative regulation of BRCA1 expression. 
  The observed delay in mortality among homo-
zygous transgenic mice expressing wild-type BRCA1 
following a DMBA treatment is consistent with a tu-
mor-suppressor function for BRCA1 (Fig. 7A, 7B). In 
this report, we document for the first time, in vivo ex-
perimental evidence that overexpression of wild-type 
BRCA1 provides protection to the mammary gland 
against the development of mutagen-induced neopla-
sia. In contrast, transgenic mice expressing BRCA1sv 
experienced an accelerated mortality due to 
DMBA-induced mammary tumors. Unlike the 
BRCA1sv mice, the outcome of DMBA-induced 
mammary tumors in BRCA1 t340 homozygous trans-
genic lines was not affected (Fig. 7A). Although we 
cannot rule out dosage effects, the differential result 
between BRCA1sv and BRCA1t340 lines suggests that 
if a dominant-negative mechanism of action by 
BRCA1sv is the cause of the observed acceleration in 
mortality, then this function does not map to the 
BRCA1 RING domain. The modulation of 
DMBA-induced mortality by either the MMTV- 
BRCA1 or MMTV-BRCA1sv transgene was specific to 
the mammary gland, recognizing the relative tissue 
specificity of the MMTV promoter. While both the 
wild type and sv BRCA1 constructs promoted early 
development of the mammary glands, our results 
would suggest that an intact ring finger is essential for 
tumor suppression by BRCA1. Although MMTV 
driven-transgene expression was detected in the sali-
vary gland and lung (Fig. 4), transgenic lines were not 
influenced in their response to DMBA in these or other 
tissues (Fig. 7B). 
  Results from this study demonstrate that 
MMTV-BRCA1 and MMTV-BRCA1sv transgenic mice 
exhibit accelerated mammary gland development. The 
finding is consistent with those previous studies, 
which indicate a role for Brca1 in promoting mammary 
epithelial cell proliferation and differentiation and 
suggests that the human and murine homologues of 
BRCA1 are, at least in some respects, functionally 
similar. Additionally, if proliferative effects occur 
through similar mechanisms in the case of both Brca1 
and BRCA1, our observations on the effects of splice 
variant expression indicate that these do not require 
the presence of the N-terminal RING domain.  
Our current observations on the effects of BRCA1 
on both epithelial cell proliferation and mammary 
tumor formation stand in contrast to a previous report 
of effects of this splice variant in cultured tumor cells 
[22], in which an anti-proliferative effect of 
RING-deleted BRCA1 was observed. Growth inhibi-
tion in human cell lines mediated by overexpression of 
an additional N-terminal BRCA1 deletion mutant [40] 
has also been previously reported. This discrepancy 
may reflect differences in BRCA1 function in cultured 
neoplastic cells compared to normal epithelium in 
mice. This difference in effect for BRCA1 in normal 
cells is supported by conditional mammary gland 
Brca1 knockouts that exhibit a failure to develop in the 
absence of Brca1 [36]. In addition, our data suggest the 
possibility of dominant negative interactions between 
wild-type Brca1 and splice variant BRCA1 in trans-
genic animals that depend on intact C-terminal se-
quences, but not the intact RING domain. This hy-
pothesis is supported by studies that have demon-
strated that the tandem BRCT domains of BRCA1 can 
interact to form a globular unit [41-43] that shares 
structural similarity with that formed by the BRCT 
domains of 53BP1 [44,45] and forms a phospho-protein 
recognition domain [46,47]. In the case of another 
BRCT-containing protein, Crb2, these structures have 
been reported to form homo-oligomers [48]. It is con-
ceivable that the localization of these and other pro-
teins to sites of DNA damage-associated nuclear foci 
may involve the formation of similar higher-order 
oligomer structures; however, such oligomerization 
could also provide the structural basis for dominant 
negative interactions. Abrogation of normal Brca1 
function by the splice variant may not recapitulate the 
blunted morphogenesis observed early in Brca1 
knockout mice because MMTV-directed transgene 
expression tends to become most pronounced in 
mammary epithelium only after puberty [49]. 
It is interesting that the naturally occurring mu-
tant (t340) had essentially no effect on the transgenic 
phenotype, suggesting at least for this particular mu-
tation and perhaps all truncating mutations, there is no 
dominant negative effect leading to breast cancer de-
velopment in BRCA1 patients. Our results also suggest 
that alternatively spliced forms of BRCA1 may have 
modulating effects on BRCA1 function and should be a 
focus for future inquiry. Future studies with these 
transgenic animals may further define the functions of 
BRCA1 during mammary gland development and re-
late functions to models of breast cancer, its prevention, 
and its treatment. Additional studies will be aimed at 
confirming the observation that increased expression Int. J. Biol. Sci. 2007, 3 
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of wild type BRCA1 delays mammary tumor forma-
tion as it may have relevance to breast cancer preven-
tion strategies.  
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